Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired
Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.
How this was made
The 30-second read
Why it matters
Traders can act on discrete catalysts: ENTX’s $275M financing, GOSS’s September 2026 NDA filing expectation, FBRX’s $77 cash acquisition offer, and OMER’s competitive relief from AZN’s Ultomiris Phase 3 failure. Other names (TVGN, TRAX) are more momentum/pipeline narrative than a single new event.
Market read
This is a catalyst-driven tape read: one large financing, one NDA-timing milestone, one cash takeover, and one competitive setback that can reprice near-term probabilities and deal spreads.
What to watch
For GOSS, NDA filing timing does not guarantee approval; for OMER, Ultomiris failure helps but does not remove all competitive or payer dynamics; for FBRX, deal spread depends on regulatory and closing conditions not detailed here.
Background
The article is a multi-name biotech gainer roundup highlighting capital raises, regulatory milestones, an acquisition, and a competitive read-through from AstraZeneca’s Phase 3 outcome.
Ticker impact
Entera Bio announced an oversubscribed private placement expected to generate about $275M gross proceeds, closing around July 28, 2026.
Likely supports downside risk control via cash runway, but dilution expectations can cap upside.
A large, oversubscribed raise with a defined close date is actionable for positioning around dilution and funding needs.
Gossamer said it expects to file a Seralutinib NDA in September 2026 after a productive FDA Pre-NDA Type B meeting and received minutes.
Bias to further upside as traders price the September NDA filing window.
The article provides specific regulatory timing (September 2026) plus FDA meeting minutes, which is directly tradable.
Forte Biosciences agreed to be acquired by argenx for $77 per share in cash, valuing equity at about $2.2B, expected to close in Q3 2026.
Shares may track toward deal value, with volatility around deal conditions and closing risk.
The offer price, consideration type, and expected closing quarter are concrete deal terms.
Tevogen Bio jumped on no specific news, while the company is evaluating acquisitions of an MSO and a CRO to add about $100M annual revenue if completed.
Near-term trading likely remains headline-driven and volatile until deal specifics emerge.
The article frames acquisitions as evaluation, not a signed transaction, and explicitly notes no specific news for the jump.
First Tracks Biotherapeutics, a recent Nasdaq spin-off, is advancing multiple antibody programs including Rosnilimab Phase 2b completion and other active trials.
Potential continuation of momentum tied to ongoing trial readouts rather than a single event.
The article emphasizes performance since debut and describes pipeline status without a new trial result or filing date.
Omeros shares rose after AstraZeneca reported Ultomiris failed the primary endpoint in a Phase 3 trial for HSCT-TMA.
Likely continued relative outperformance versus biotech peers tied to HSCT-TMA competition.
The catalyst is a specific Phase 3 failure at AstraZeneca, which can change competitive expectations for Omeros.
Market effects
Biotech sentiment is supported by multiple company-specific catalysts across regulatory progress, capital raises, and deal activity.
Primarily US-listed biotech tape impact, with cross-name read-through from AstraZeneca’s Phase 3 result.
Limited global macro linkage; main effect is competitive positioning in rare disease and deal-driven repricing.
Counterpoint
Financing and deal headlines can reverse quickly if terms imply dilution risk or if acquisition conditions face delays; competitive read-through may be overstated without label/market share data.
Key entities
- companyEntera Bio Ltd.
Oversubscribed private placement financing expected to raise about $275M gross proceeds.
- companyGossamer Bio, Inc.
Seralutinib NDA expected in September 2026 after FDA Pre-NDA Type B meeting and minutes.
- companyForte Biosciences Inc.
Agreed to be acquired by argenx for $77 per share in cash, expected to close in Q3 2026.
- companyTevogen Bio Holdings Inc.
Evaluating MSO and CRO acquisitions that could add about $100M annual revenue if completed.
- companyFirst Tracks Biotherapeutics Inc.
Pipeline update across antibody therapeutics following Nasdaq debut/spin-off.
